Jacob Johnson learned that he was a carrier for the BRCA2 gene in 2013 after testing was recommended due to a strong history of breast cancer among relatives — including his mother, several aunts, a ...
The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...
A bill moving through the Tennessee legislature would require insurance companies to cover biomarker testing, a screening that can detect early signs of disease.
The median OS was 28 months with abiraterone-prednisone, 37 months with olaparib alone, and 68 months with abiraterone-prednisone-olaparib. In patients with metastatic castration-resistant prostate ...
Io Therapeutics, Inc. in Spring, Texas, announces collaborative publication of data from preclinical studies with scientists at The University of Texas MD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results